The growing role of clinical and genomic databases in the development of antifungal strategies

Research output: Contribution to journalArticle

Abstract

Decisions about the prophylactic and empiric use of antifungal agents in immunosuppressed recipients of solid-organ transplants and hematopoietic stem cell transplantation (HSCT) call for up-to-date knowledge regarding which infections are most likely to develop in the populations at risk, but rapidly changing immunosuppressive regimens and the costs of large-scale clinical trials require new ways of gathering these data. Leveraging new clinical data from electronic databases to better understand the changing epidemiology of invasive fungal infection and the patterns of risk factors for adverse effects of antifungal treatment offers a major challenge and opportunity. Evidence-based integration of results generated from traditional prospective clinical trials, clinical and genomic databases, and laboratory-based investigations will enable us to maximize the potential benefits of antifungal agents and reduce their risks.

Original languageEnglish (US)
Pages (from-to)190-192
Number of pages3
JournalCurrent Fungal Infection Reports
Volume5
Issue number4
DOIs
StatePublished - 2011

Fingerprint

Antifungal Agents
Clinical Trials
Databases
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Epidemiology
Transplants
Costs and Cost Analysis
Infection
Therapeutics
Invasive Fungal Infections

Keywords

  • Adverse effects
  • Antifungal agents
  • Clinical databases
  • Databases
  • Fungal infection
  • Genomic databases
  • Genomics
  • Hematopoietic stem cell transplantation
  • HSCT
  • Immunosuppression
  • Prophylaxis
  • Risk factors
  • Solid-organ transplants
  • Treatment

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

@article{2595a4eb1ece41d6a89f8f290cf1f5d1,
title = "The growing role of clinical and genomic databases in the development of antifungal strategies",
abstract = "Decisions about the prophylactic and empiric use of antifungal agents in immunosuppressed recipients of solid-organ transplants and hematopoietic stem cell transplantation (HSCT) call for up-to-date knowledge regarding which infections are most likely to develop in the populations at risk, but rapidly changing immunosuppressive regimens and the costs of large-scale clinical trials require new ways of gathering these data. Leveraging new clinical data from electronic databases to better understand the changing epidemiology of invasive fungal infection and the patterns of risk factors for adverse effects of antifungal treatment offers a major challenge and opportunity. Evidence-based integration of results generated from traditional prospective clinical trials, clinical and genomic databases, and laboratory-based investigations will enable us to maximize the potential benefits of antifungal agents and reduce their risks.",
keywords = "Adverse effects, Antifungal agents, Clinical databases, Databases, Fungal infection, Genomic databases, Genomics, Hematopoietic stem cell transplantation, HSCT, Immunosuppression, Prophylaxis, Risk factors, Solid-organ transplants, Treatment",
author = "Shmuel Shoham and Ostrander, {Darin Bruce}",
year = "2011",
doi = "10.1007/s12281-011-0071-9",
language = "English (US)",
volume = "5",
pages = "190--192",
journal = "Current Fungal Infection Reports",
issn = "1936-3761",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - The growing role of clinical and genomic databases in the development of antifungal strategies

AU - Shoham, Shmuel

AU - Ostrander, Darin Bruce

PY - 2011

Y1 - 2011

N2 - Decisions about the prophylactic and empiric use of antifungal agents in immunosuppressed recipients of solid-organ transplants and hematopoietic stem cell transplantation (HSCT) call for up-to-date knowledge regarding which infections are most likely to develop in the populations at risk, but rapidly changing immunosuppressive regimens and the costs of large-scale clinical trials require new ways of gathering these data. Leveraging new clinical data from electronic databases to better understand the changing epidemiology of invasive fungal infection and the patterns of risk factors for adverse effects of antifungal treatment offers a major challenge and opportunity. Evidence-based integration of results generated from traditional prospective clinical trials, clinical and genomic databases, and laboratory-based investigations will enable us to maximize the potential benefits of antifungal agents and reduce their risks.

AB - Decisions about the prophylactic and empiric use of antifungal agents in immunosuppressed recipients of solid-organ transplants and hematopoietic stem cell transplantation (HSCT) call for up-to-date knowledge regarding which infections are most likely to develop in the populations at risk, but rapidly changing immunosuppressive regimens and the costs of large-scale clinical trials require new ways of gathering these data. Leveraging new clinical data from electronic databases to better understand the changing epidemiology of invasive fungal infection and the patterns of risk factors for adverse effects of antifungal treatment offers a major challenge and opportunity. Evidence-based integration of results generated from traditional prospective clinical trials, clinical and genomic databases, and laboratory-based investigations will enable us to maximize the potential benefits of antifungal agents and reduce their risks.

KW - Adverse effects

KW - Antifungal agents

KW - Clinical databases

KW - Databases

KW - Fungal infection

KW - Genomic databases

KW - Genomics

KW - Hematopoietic stem cell transplantation

KW - HSCT

KW - Immunosuppression

KW - Prophylaxis

KW - Risk factors

KW - Solid-organ transplants

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84905124632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905124632&partnerID=8YFLogxK

U2 - 10.1007/s12281-011-0071-9

DO - 10.1007/s12281-011-0071-9

M3 - Article

VL - 5

SP - 190

EP - 192

JO - Current Fungal Infection Reports

JF - Current Fungal Infection Reports

SN - 1936-3761

IS - 4

ER -